The BPaLM regimen promises a breakthrough in MDR-TB treatment with a shorter, all-oral approach. However, high costs, limited ...

Objective: To assess the efficacy, safety and tolerability of moxifloxacin, an 8-methoxy fluoroquinolone, in patients with respiratory tract infections (RTIs) treated in general practice in Germany.

An equitable TB programme is one where every individual receives the highest quality of person-centred care that takes into ...

India accounts for 30 per cent of the global TB burden and 62 per cent of multidrug-resistant cases. Despite a 17.7 per cent ...

The WHO report noted that five countries contributed to 56 percent of the worldwide TB cases—India (26 percent), Indonesia ...

Objective: To assess the efficacy, safety and tolerability of oral moxifloxacin in outpatients with respiratory tract infections treated in general practices in Germany with the focus on community ...

Tuberculosis, an ongoing pandemic, highlights and exacerbates global disparities. With the prevailing model of standardised treatment in vertical health programmes, it is unsurprising that ...

Govt launches 826 drug-resistant centers under the 100-day TB-Mukt Bharat Abhiyan to combat tuberculosis. Get the latest ...

In adults and adolescents aged 14 years and older with rifampin-resistant, fluoroquinolone-susceptible pulmonary TB, the panel recommended a 6-month regimen consisting of bedaquiline, pretomanid, ...

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ...